FDA-appointed panel to consider Abbott's Xience stent data Thursday

11/27/2007 | NYTimes.com · Wall Street Journal, The

A federal advisory panel will meet Thursday to consider whether clinical trial data on Abbott Laboratories' Xience drug-coated stent sufficiently proves the device is safe and effective. The group will study just-released findings of a trial comparing Xience with Boston Scientific Corp.'s Taxus 2 stent and evaluate if ongoing patient trials should be extended before the agency considers whether to approve the device. The panel will make a recommendation to the FDA concerning approval of the device.

View Full Article in:

NYTimes.com · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY